CRANBURY, N.J., Sept. 9 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., the cancer metabolism company, today announced that its CEO, Robert Shorr, Ph.D., D.I.C., will be speaking and Co-Chairing The Center for Business Intelligence's (CBI's) 4th Annual Oncology Clinical Trials Summit and chairing a panel on cancer metabolism at the Life Sciences Summit organized by the Center for Biotechnology, State University of Stony Brook, NY. Both conferences will be held in September - the 14th and 22nd respectively. Cornerstone is the leader in the discovery and development of cancer therapies based on the science of cancer metabolism.
Dr. Shorr's accomplishments span the spectrum from technological innovation to the founding, financing, and guiding to full commercialization of biotechnology ventures. He has focused most of his career on the research and discovery of the biochemical basis of neurotransmitter and hormone receptors; their link to metabolic events; their role in pathology, and the design and discovery of therapeutic agents. As CEO of Cornerstone Pharmaceuticals, Dr. Shorr oversees the development, human clinical trials, and FDA approvals of safe and effective novel metabolic targeted drugs and delivery technology for dramatic improvements in cancer disease management.
Prior to Cornerstone, Dr. Shorr served as Vice President, Science and Technology/Chief Scientist for United Therapeutics/Unither, where he was an inventor of PEGylated prostacylcin for pulmonary hypertension. As Vice President of Science and Technology for Enzon Inc., he was responsible for the development and regulatory approval of the blockbuster drug PEG INTRON A.
Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters, and conference proceedings, and has more than 150 inventions and issued or pending patents worldwide.
"Dr. Shorr is a renowned expert in cancer metabolism and has a great body of knowledge and numerous insights